Shenzhen Stock Exchange: We have received your inquiry letter dated May 7, 2026, regarding the application of Zhejiang Anglikang Pharmaceutical Co., Ltd. for a targeted stock issuance (Inquiry Letter [2026] No. 120026) (hereinafter referred to as "Inquiry Letter"). Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Anglikang," "the issuer," or "the company") has, together with Dongfang Securities Co., Ltd. (hereinafter referred to as "Dongfang Securities," "the sponsor institution," or "the sponsor"), the issuer's lawyer Zhejiang Tianche Law Firm (hereinafter referred to as "Tianche Lawyer," "the issuer's lawyer," or "the lawyer"), and the reporting accountant Tianjian Accounting Firm (Special General Partnership) (hereinafter referred to as "Tianjian Accountant," "the reporting accountant," or "the accountant"), diligently discussed, verified, and implemented the issues raised in the Inquiry Letter, and provided responses accordingly. The specific response content is attached for your review.
Regarding the interpretation, format, and supplementary updates of the response content:
- Unless otherwise specified, the abbreviations or definitions used in this response are the same as those in the "Zhejiang Anglikang Pharmaceutical Co., Ltd. 2025 A-Share Targeted Issuance Prospectus" (hereinafter referred to as "the Prospectus").
- If there are discrepancies between the total counts and the sum of listed values in this response, they are due to rounding.
- There may be slight differences between the subtotal and total in some tables in this response due to rounding during calculations. The font in this inquiry response represents the following meanings:
- Questions listed in the inquiry letter are in bold font.
- Responses to the inquiry letter are in regular font.
- Modifications to the responses, prospectus, and other application documents are in italic bold font.
Table of Contents
Question 1............................................................................................................................. 4
I. Explanation from the issuer .................................................................................................... 5
II. Additional disclosure of relevant risks by the issuer ................................................................ 57
III. Verification by intermediary institutions ................................................................................ 58
Question 2........................................................................................................................... 64
I. Explanation from the issuer .................................................................................................. 65
II. Additional disclosure of relevant risks by the issuer ................................................................ 112
III. Verification by intermediary institutions ................................................................................ 114